Photo by Kwanchai Lerttanapunyapron/EyeEm/Getty Images
PathAI, a Boston-based artificial intelligence pathology company, has closed a Series C funding round worth $165 million.
The round was co-led by D1 Capital Partners and Kaiser Permanente, with additional participation from General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, and strategic partners Bristol-Myers Squibb Company, Labcorp and Merck Global Health Innovation Fund.
With the new funds, PathAI plans to accelerate product development to expand its suite of applications beyond oncology and nonalcoholic steatohepatitis. It will also seek new partnerships with pharmaceutical and diagnostic organizations.
This funding brings PathAI’s total amount raised to date to more than $255 million.
Palo Alto, California-based SymphonyRM raised $25 million in its Series B funding round led by TT Capital Partners. Past investor Adams Street Partners also participated in the round.
SymphonyRM has now raised $35 million after the company closed a $10 million Series A in 2019.
In addition to its financial support, TTCP Vice President Donnacha O’Sullivan joined SymphonyRM’s board of directors.
“The doctor-patient relationship is core to healthcare delivery and improved health outcomes. SymphonyRM’s capabilities further this important relationship, while helping providers become even more successful in the era of value-based care,” O’Sullivan said in a statement. “We look forward to collaborating with SymphonyRM’s strong management team as they continue advancing the use of actionable data to help health systems and consumers thrive.”
The company will invest the capital into sales and marketing to expand the use of its platform that helps provider and payer organizations engage patients with data and AI. It plans to specifically focus on the payer space, according to the announcement.
Artificial, the maker of an automated platform for biopharma labs, scored $21.5 million in Series A funding. The round was led by M12, Microsoft’s venture fund, along with Playground Global and AME Cloud Ventures.
“At Artificial, we believe that the scientific process is as much an art as it is science so any lab automation platform must keep the human-in-the-loop. This is why we’ve built a single, easy-to-use platform that orchestrates everything in a lab from the robots, automation instruments, data, and people,” David Fuller, CEO and cofounder of Artificial, said in a statement.
“Rather than adding another software tool to their tech stack, we want to orchestrate a lab’s software, hardware, and people so they can seamlessly capture their scientific intent and map it to automated and augmented execution.”
The company will deploy the funds into product development, hiring additional team members and furthering their life science partnerships. Additionally, Dr. Kouki Harasaki from M12 and Peter Barrett from Playground Global have joined Artificial’s board of directors.
Medication adherence platform emocha Health landed $6.2 million in an oversubscribed Series A funding round led by Claritas Health Ventures. Healthworx, Kapor Capital and PTX Capital also invested in the round.
emocha said it will use the capital to support integrations and to grow its remote clinical team of nurses and pharmacists that help users stay on top of their medication regimen.
Theresa Sexton, managing partner at Claritas Health Ventures, will join the company's board of directors as a part of its investment.
"After twelve months of tremendous expansion, we are at an inflection point," Sebastian Seiguer, CEO of emocha, said in a statement. "Our new partners will enable us to help millions of infectious and chronic disease patients across the country take every dose of medication properly. I cannot believe that society continues to tolerate the devastating outcomes associated with medication non-adherence problems, especially in this time of digital transformation. The opportunity for emocha to meaningfully change health trajectories – especially for vulnerable populations – is enormous."
DeepScribe, an ambient AI medical scribe tool, has closed a seed round worth $5.2 million.
Bee Partners led the round with additional participation from new backers Industry Ventures and Stage II Capital, along with existing investors Tsingyuan Ventures, 1984 Ventures, Wavemaker 360, Supernode Ventures, Skydeck, Plug and Play, and Sequoia Scout Fund.
The scribing tool combines natural language processing with deep learning processes to listen when doctors interact with their patients, take notes on the conversation and transfer the summary into a compliant note in the doctor’s EHR system.
“The value of DeepScribe goes much deeper than note-taking,” said DeepScribe cofounder Akilesh Bapu in a statement. “It’s about giving doctors the freedom to focus on caregiving and give patients their full attention. Studies show that patient satisfaction is directly correlated with facetime with their physicians. That’s what we mean when we talk about bringing the joy of care back to medicine. It’s about restoring that relationship between doctor and patient.”
DeepScribe will use the funds to accelerate company growth by building out its machine learning and product engineer team as well as its sales and implementation teams.
"We’ll continue to push our technology to the limits of the state of the art, and expand our product offerings and functionality to cater to every type of physician or specialty,” Bapu said.